Humanized Mouse Model Market
Humanized Mouse Models being extensively used to develop Treatment and Diagnostics breakthroughs for Various Ailments, more specifically, Cancer
Humanized Mouse Model Market by Model Type, End User & Region - Forecast 2022-2032
Humanized Mouse Model Market Outlook (2022-2032)
[300 Pages Report] The global humanized mouse model market is expected to be valued at US$ 92.5 Million in 2022. Throughout the decade spanning 2022-2032, the industry is poised to register a value CAGR worth 5.5% to reach US$ 167.3 Million. Soaring demand from the healthcare sector for more active screening of novel drug candidates discovered to cure a variety of chronic diseases such as cardiovascular conditions, diabetes, and cancers have remained one of the key aspects of augmented research activities in the field of humanized mice models. The market for humanized mouse model registered a CAGR of 4.9% in the historical period 2016-2021.
|
Data Points |
Key Statistics |
|
Humanized Mouse Model Market Value (2022) |
US$ 92.5 Million |
|
Humanized Mouse Model Market Forecast Value (2032) |
US$ 167.3 Million |
|
Humanized Mouse Model Market CAGR (2022-2032) |
5.5% CAGR |
The use of genetically engineered mice in experimental medical research has led to significant advances to understand the disease and human health. With the development of gene targeting and transgenic methods and recent innovations in gene-editing technologies, the manipulation of the mouse genome has become more refined. There is an extensive genetic similarity between humans and mice; it is also recognized that even very subtle sequence differences between the two species can have important functional consequences for the respective individual gene functions.
Also, some genes have been identified in humans that do not have orthologous mouse counterparts. This divergence limits the utility of mouse models in predicting gene function as a reliable tool for preclinical research. These genetically “humanized” mice have the potential to provide more reliable in vivo data concerning human gene function in normal physiology and disease. As a result, there is growing interest in the generation of genetically engineered mice that express an orthologous human gene.
Let us know your requirement to get
100% FREE customization
Humanized Mouse Model Demand Analysis (2016 to 2021) Vs Market Outlook (2022 to 2032)
The global demand for humanized mouse model is projected to increase at a CAGR of 5.5% during the forecast period between 2022 and 2032, reaching a total of US$ 167.3 Million in 2032, according to a report from Future Market Insights (FMI). From 2016 to 2021, sales witnessed significant growth, registering a CAGR of 4.9%.
Research is playing a key role in the development of humanized mouse models. This has led to changing dynamics of the healthcare and pharmaceutical sector. Moreover, different types of ailments have increased the requirement of personalized medicine, further bolstering the demand for humanized mouse models.
Which are Some Prominent Drivers of Humanized Mouse Model Market?
Research and Personalized Medicines accelerating growth of Humanized Mouse Model Market
Continuous support for research activities in the form of grants and investments, increased R&D activities by biotechnology and pharmaceutical companies, the surge in the number of research activities involving humanized mouse models, and growing consumption of personalized medicines have attributed to the growth of overall humanized mouse model market.
The CD34 cell-based humanized mouse model segment is expected to have a larger share in the cell-based humanized mouse model market. These models are used for long-term studies in the fields of immuno-oncology, host disease, and infectious disease. Thus, the growing application areas of CD34 models are expected to trigger the demand for these models.
The growth of these segments is attributed due to growing funds from various governments to carry out increasing research activities and research studies in cancer.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Humanized Mouse Model Market?
Expensive Nature restraining uptake of Humanized Mouse Models
Despite numerous drivers, one of the foremost factors impeding is the high cost of humanized models which is limiting their usage in research as humanized models used in experiments can charge thousands of dollars even in the case of a single patient. Besides, using humanized models in government-funded basic research can also be cost-prohibitive thus, challenging the global market growth.
Region-Wise Insights
Pharmaceutical Companies in North America Contributing to Humanized Mouse Model Market Growth?
Evolution of medical research influencing market growth
North America accounts for a majority share, capturing 41.5% revenue of the global humanized mouse model market in 2022. This large share is attributed due to increased R&D spending by pharmaceutical companies and increasing biomedical research. The presence of prominent market players and the evolution of pharmaceutical as well as research sectors in this region are likely to act as principal drivers.
According to a recent research publication, rat and mouse models encompass 99.3% of the mammals used in 16 large American organizations. Thus, a high consumption rate of these models in the region boosts revenue growth. The North American region has witnessed immense technological advancement resulting in the development of the transgenic mouse, knock-in mouse, and knock-out mouse.
Efforts to embed mouse bone marrow with human hematopoietic stem cells and mouse liver with human hepatocytes, permitting them to eradicate the limitations of the orthodox xenograft models, have also offered new growth prospects to the market.
Research Changing the Dynamics for Gene Therapy in Humanized Mouse Model Market in Europe?
Healthcare Budgets creating lucrative opportunities for Research and Development
Europe held the second-largest market share, acquiring a 33.4% share, backed by the rise in research activities involving the use of rodent models. In September 2021, a team of researchers from the Universitat Autònoma de Barcelona (UAB); Spain generated a rat model which could recapitulate the disabling alterations observed in patients with Morquio A disease or Mucopolysaccharidosis type IVA.
The scientists have also successfully tested gene therapy which treats changes in the whole body observed in rat models with Morquio A disease. Such kinds of research activities can potentially result in the discovery of new remedies which could treat young patients with life-threatening alterations. This also reassures drug developers to use rodent models for drug discovery and development.
Expanding healthcare budgets and favorable government policies have boosted the development of new drugs for the treatment of cancer. Increasing healthcare spending and the prevalence of chronic diseases have augmented the demand for the Humanized Mouse Model in the region.
Increase in Application of Humanized Mouse Model for Infectious Diseases Bolstering Market Growth in Asia Pacific?
Biopharmaceuticals increasing dependency on Humanized Mouse Models
The humanized mouse model market is expected to witness a high growth rate in the Asia-Pacific region reasons being increasing investments from the private sector and government in the life sciences sector, research in regenerative medicines, increase in animal research, rising focus on personalized medicines, growth in translational and biomedical research, growth in the pharmaceutical industries, and rising pharmaceutical and biotechnology R&D activities in these regions.
Moreover, the rising numbers of contract research organizations in the region and bigger funds being poured into the R&D sector linked with the pharmaceuticals and biopharmaceuticals sectors have boosted the human mouse model market in Asia Pacific.
The region is anticipated to remain a rewarding regional humanized mice models market throughout the next few years due to the augmented influx of research activities in the region’s CMOs. The increasing application of humanized mouse model in the Immunology and Infectious Diseases and oncology segment acts as the prominent driver of humanized mouse model market in the region.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category-Wise Insights
Prevalence of Cancer Fueling Growth of Research for Oncology in Humanized Mouse Model Market?
Rise in Cancer Research Activities increasing dependency on Humanized Mouse Models
Based on application, the market is segmented into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications.
The oncology segment is expected to witness the highest growth, owing to the rising number of cancer research activities and increasing innovation to develop humanized mouse models tailored to meet the specific needs of cancer research. Thus, oncology is expected to procure 35% market share for humanized mouse model market.
How Start-ups are Adding Value to the Global Humanized Mouse Model Market?
- Founded in 2009, Biocytogen, a Beijing-headquartered CRO that specialized in gene-targeted animal models and related services, has just closed a 410 million Chinese yuan ($65 million) series C round. On top of an existing 15,000-square-meter facility for mouse model production, the company just began construction of a 35,000-square-meter R&D base in Beijing and it plans to start building an 80,000-square-meter model supply facility near Shanghai in October.
- Founded in 2017, a bit.bio - a Cambridge, UK, based company announced the first close of their Series B financing of $103 million. The company wants to revolutionize clinical research and drug discovery by producing precisely engineered batches of human cells.
Who are the Key Players in the Global Humanized Mouse Model Market?
Some of the major market players in humanized mouse model market include Ingenious Targeting Laboratory, Axenis S.A.S, Trans Genic Inc., Horizon Discovery Group PLC, HuMurine Technologies, Champions Oncology Inc., Genoway S.A., Crown Bioscience Inc., Taconic Biosciences Inc., The Jackson Laboratory, and Vitalstar Biotechnology Co. Ltd.
- In September 2021, genOway, the biotechnology company dedicated to the design and development of preclinical models, announced the acquisition of Axenis, a company dedicated to the development of immunocompromised models for the validation of new and innovative therapeutics.
- In January 2022, Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announced the launch of the huNOG-EXL EA (Early Access) humanized immune system (HIS) mouse. This product expands Taconic’s widely used HIS portfolio. huNOG-EXL EA significantly lengthens the study window during which a myeloid-lineage HIS mouse model can be used successfully.
- In October 2021, The Jackson Laboratory (JAX), a U.S.-based nonprofit biomedical research institution, announced the acquisition of Charles River Laboratories Japan’s Research Models & Services (RMS) business as a wholly owned subsidiary. The Japan-based organization, which will be called The Jackson Laboratory Japan, has approximately 250 employees and three production sites in Atsugi, Hino, and Tsukuba, and an administrative office in Yokohama.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 5.5% from 2022 to 2032 |
|
Market Value in 2022 |
US$ 92.5 Million |
|
Market Value in 2032 |
US$ 167.3 Million |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ Million, and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Covered in the Humanized Mouse Model Industry Survey
Humanized Mouse Model Market by Model Type:
- Genetic Humanized Mouse Model
- Cell-based Humanized Mouse Model
- CD34
- PBMC
- BLT
Humanized Mouse Model Market by Application:
- Humanized Mouse Models for Oncology
- Humanized Mouse Models for Immunology and Infectious Diseases
- Humanized Mouse Models for Neuroscience
- Humanized Mouse Models for Toxicology
- Humanized Mouse Models for Hematopoiesis
- Humanized Mouse Models for Other Applications
Humanized Mouse Model Market by End User:
- Humanized Mouse Models for Pharmaceutical & Biotechnology Companies
- Humanized Mouse Models for Contract Research Organizations
- Humanized Mouse Models for Academic & Research Institutions
Humanized Mouse Model by Region:
- North America Humanized Mouse Model Market
- Europe Humanized Mouse Model Market
- Asia Pacific Humanized Mouse Model Market
- Middle East & Africa Humanized Mouse Model Market
- Latin America Humanized Mouse Model Market
Frequently Asked Questions
FMI projects the global humanized mouse model market to expand at a 5.5% value CAGR by 2032
North America accounts for a majority share, capturing 41.5% revenue of the global humanized mouse model market in 2022
Ingenious Targeting Laboratory, Axenis S.A.S, Trans Genic Inc., Horizon Discovery Group PLC, HuMurine Technologies, Champions Oncology Inc., Genoway S.A., Crown Bioscience Inc., Taconic Biosciences Inc., The Jackson Laboratory, and Vitalstar Biotechnology Co. Ltd are some prominent humanized mouse model manufacturers
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Model Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Model Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Model Type, 2022-2032
5.3.1. Genetic
5.3.2. Cell-based
5.3.3. CD34
5.3.4. PBMC
5.3.5. BLT
5.4. Y-o-Y Growth Trend Analysis By Model Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Model Type, 2022-2032
6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2022-2032
6.3.1. Oncology
6.3.2. Immunology and Infectious Diseases
6.3.3. Neuroscience
6.3.4. Toxicology
6.3.5. Hematopoiesis
6.4. Y-o-Y Growth Trend Analysis By Application, 2017-2021
6.5. Absolute $ Opportunity Analysis By Application, 2022-2032
7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032
7.3.1. Pharmaceutical & Biotechnology Companies
7.3.2. Contract Research Organizations
7.3.3. Academic & Research Institutions
7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021
7.5. Absolute $ Opportunity Analysis By End User, 2022-2032
8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Model Type
9.2.3. By Application
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Model Type
9.3.3. By Application
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Model Type
10.2.3. By Application
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Model Type
10.3.3. By Application
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Model Type
11.2.3. By Application
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Model Type
11.3.3. By Application
11.3.4. By End User
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. India
12.2.1.5. Malaysia
12.2.1.6. Singapore
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of APAC
12.2.2. By Model Type
12.2.3. By Application
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Model Type
12.3.3. By Application
12.3.4. By End User
12.4. Key Takeaways
13. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Model Type
13.2.3. By Application
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Model Type
13.3.3. By Application
13.3.4. By End User
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. U.S.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Model Type
14.1.2.2. By Application
14.1.2.3. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Model Type
14.2.2.2. By Application
14.2.2.3. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Model Type
14.3.2.2. By Application
14.3.2.3. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Model Type
14.4.2.2. By Application
14.4.2.3. By End User
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Model Type
14.5.2.2. By Application
14.5.2.3. By End User
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Model Type
14.6.2.2. By Application
14.6.2.3. By End User
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Model Type
14.7.2.2. By Application
14.7.2.3. By End User
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Model Type
14.8.2.2. By Application
14.8.2.3. By End User
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Model Type
14.9.2.2. By Application
14.9.2.3. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Model Type
14.10.2.2. By Application
14.10.2.3. By End User
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Model Type
14.11.2.2. By Application
14.11.2.3. By End User
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Model Type
14.12.2.2. By Application
14.12.2.3. By End User
14.13. Malaysia
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Model Type
14.13.2.2. By Application
14.13.2.3. By End User
14.14. Singapore
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Model Type
14.14.2.2. By Application
14.14.2.3. By End User
14.15. Australia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Model Type
14.15.2.2. By Application
14.15.2.3. By End User
14.16. New Zealand
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Model Type
14.16.2.2. By Application
14.16.2.3. By End User
14.17. GCC Countries
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Model Type
14.17.2.2. By Application
14.17.2.3. By End User
14.18. South Africa
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Model Type
14.18.2.2. By Application
14.18.2.3. By End User
14.19. Israel
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Model Type
14.19.2.2. By Application
14.19.2.3. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Model Type
15.3.3. By Application
15.3.4. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Axenis S.A.S.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Trans Genic Inc.
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Horizon Discovery Group PLC
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. HuMurine Technologies
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Champions Oncology Inc.
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Genoway S.A.
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Crown Bioscience Inc.
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Taconic Biosciences Inc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. The Jackson Laboratory
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Vitalstar Biotechnology Co. Ltd.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Market Value (US$ Mn) Forecast by Model Type, 2017-2032
Table 3: Global Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 4: Global Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 5: North America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 6: North America Market Value (US$ Mn) Forecast by Model Type, 2017-2032
Table 7: North America Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 8: North America Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 9: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 10: Latin America Market Value (US$ Mn) Forecast by Model Type, 2017-2032
Table 11: Latin America Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 12: Latin America Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 13: Europe Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Europe Market Value (US$ Mn) Forecast by Model Type, 2017-2032
Table 15: Europe Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 16: Europe Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 17: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 18: Asia Pacific Market Value (US$ Mn) Forecast by Model Type, 2017-2032
Table 19: Asia Pacific Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 20: Asia Pacific Market Value (US$ Mn) Forecast by End User, 2017-2032
Table 21: MEA Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 22: MEA Market Value (US$ Mn) Forecast by Model Type, 2017-2032
Table 23: MEA Market Value (US$ Mn) Forecast by Application, 2017-2032
Table 24: MEA Market Value (US$ Mn) Forecast by End User, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Model Type, 2022-2032
Figure 2: Global Market Value (US$ Mn) by Application, 2022-2032
Figure 3: Global Market Value (US$ Mn) by End User, 2022-2032
Figure 4: Global Market Value (US$ Mn) by Region, 2022-2032
Figure 5: Global Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 8: Global Market Value (US$ Mn) Analysis by Model Type, 2017-2032
Figure 9: Global Market Value Share (%) and BPS Analysis by Model Type, 2022-2032
Figure 10: Global Market Y-o-Y Growth (%) Projections by Model Type, 2022-2032
Figure 11: Global Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 12: Global Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 13: Global Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 14: Global Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 17: Global Market Attractiveness by Model Type, 2022-2032
Figure 18: Global Market Attractiveness by Application, 2022-2032
Figure 19: Global Market Attractiveness by End User, 2022-2032
Figure 20: Global Market Attractiveness by Region, 2022-2032
Figure 21: North America Market Value (US$ Mn) by Model Type, 2022-2032
Figure 22: North America Market Value (US$ Mn) by Application, 2022-2032
Figure 23: North America Market Value (US$ Mn) by End User, 2022-2032
Figure 24: North America Market Value (US$ Mn) by Country, 2022-2032
Figure 25: North America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 28: North America Market Value (US$ Mn) Analysis by Model Type, 2017-2032
Figure 29: North America Market Value Share (%) and BPS Analysis by Model Type, 2022-2032
Figure 30: North America Market Y-o-Y Growth (%) Projections by Model Type, 2022-2032
Figure 31: North America Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 32: North America Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 33: North America Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 34: North America Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 37: North America Market Attractiveness by Model Type, 2022-2032
Figure 38: North America Market Attractiveness by Application, 2022-2032
Figure 39: North America Market Attractiveness by End User, 2022-2032
Figure 40: North America Market Attractiveness by Country, 2022-2032
Figure 41: Latin America Market Value (US$ Mn) by Model Type, 2022-2032
Figure 42: Latin America Market Value (US$ Mn) by Application, 2022-2032
Figure 43: Latin America Market Value (US$ Mn) by End User, 2022-2032
Figure 44: Latin America Market Value (US$ Mn) by Country, 2022-2032
Figure 45: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 48: Latin America Market Value (US$ Mn) Analysis by Model Type, 2017-2032
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Model Type, 2022-2032
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Model Type, 2022-2032
Figure 51: Latin America Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 54: Latin America Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 57: Latin America Market Attractiveness by Model Type, 2022-2032
Figure 58: Latin America Market Attractiveness by Application, 2022-2032
Figure 59: Latin America Market Attractiveness by End User, 2022-2032
Figure 60: Latin America Market Attractiveness by Country, 2022-2032
Figure 61: Europe Market Value (US$ Mn) by Model Type, 2022-2032
Figure 62: Europe Market Value (US$ Mn) by Application, 2022-2032
Figure 63: Europe Market Value (US$ Mn) by End User, 2022-2032
Figure 64: Europe Market Value (US$ Mn) by Country, 2022-2032
Figure 65: Europe Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 68: Europe Market Value (US$ Mn) Analysis by Model Type, 2017-2032
Figure 69: Europe Market Value Share (%) and BPS Analysis by Model Type, 2022-2032
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Model Type, 2022-2032
Figure 71: Europe Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 72: Europe Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 74: Europe Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 75: Europe Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 76: Europe Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 77: Europe Market Attractiveness by Model Type, 2022-2032
Figure 78: Europe Market Attractiveness by Application, 2022-2032
Figure 79: Europe Market Attractiveness by End User, 2022-2032
Figure 80: Europe Market Attractiveness by Country, 2022-2032
Figure 81: Asia Pacific Market Value (US$ Mn) by Model Type, 2022-2032
Figure 82: Asia Pacific Market Value (US$ Mn) by Application, 2022-2032
Figure 83: Asia Pacific Market Value (US$ Mn) by End User, 2022-2032
Figure 84: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032
Figure 85: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 88: Asia Pacific Market Value (US$ Mn) Analysis by Model Type, 2017-2032
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Model Type, 2022-2032
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Model Type, 2022-2032
Figure 91: Asia Pacific Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 94: Asia Pacific Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 97: Asia Pacific Market Attractiveness by Model Type, 2022-2032
Figure 98: Asia Pacific Market Attractiveness by Application, 2022-2032
Figure 99: Asia Pacific Market Attractiveness by End User, 2022-2032
Figure 100: Asia Pacific Market Attractiveness by Country, 2022-2032
Figure 101: MEA Market Value (US$ Mn) by Model Type, 2022-2032
Figure 102: MEA Market Value (US$ Mn) by Application, 2022-2032
Figure 103: MEA Market Value (US$ Mn) by End User, 2022-2032
Figure 104: MEA Market Value (US$ Mn) by Country, 2022-2032
Figure 105: MEA Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 108: MEA Market Value (US$ Mn) Analysis by Model Type, 2017-2032
Figure 109: MEA Market Value Share (%) and BPS Analysis by Model Type, 2022-2032
Figure 110: MEA Market Y-o-Y Growth (%) Projections by Model Type, 2022-2032
Figure 111: MEA Market Value (US$ Mn) Analysis by Application, 2017-2032
Figure 112: MEA Market Value Share (%) and BPS Analysis by Application, 2022-2032
Figure 113: MEA Market Y-o-Y Growth (%) Projections by Application, 2022-2032
Figure 114: MEA Market Value (US$ Mn) Analysis by End User, 2017-2032
Figure 115: MEA Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 116: MEA Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 117: MEA Market Attractiveness by Model Type, 2022-2032
Figure 118: MEA Market Attractiveness by Application, 2022-2032
Figure 119: MEA Market Attractiveness by End User, 2022-2032
Figure 120: MEA Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
